BIOMARKERS FOR COMBINATION THERAPY FOR ER+ BREAST CANCER
Embodiments of the disclosure concern methods and compositions that facilitate determination of a suitable therapy for an individual in need thereof. In specific embodiments, the individual has ER+ breast cancer of a specific subtype that renders them suitable for a particular therapy and/or renders them unsuitable for a particular therapy. In specific cases, gene expression analysis determines that an individual is of Luminal B subtype and the individual is suited for combination therapy of one or more aromatase inhibitors and one or more selective estrogen receptor degraders (SERDs) and/or is not suitable for chemotherapy..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Europäisches Patentamt - (2023) vom: 19. Okt. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
ELLIS MATTHEW J [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-10-19, Last update posted on www.tib.eu: 2023-11-30, Last updated: 2023-12-08 |
---|
Patentnummer: |
WO2023172891 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA018126391 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA018126391 | ||
003 | DE-627 | ||
005 | 20231208120748.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231006s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA018126391 | ||
035 | |a (EPA)WO2023172891 | ||
035 | |a (EPA)87935904 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a ELLIS MATTHEW J |e verfasserin |4 aut | |
245 | 1 | 0 | |a BIOMARKERS FOR COMBINATION THERAPY FOR ER+ BREAST CANCER |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2023-10-19, Last update posted on www.tib.eu: 2023-11-30, Last updated: 2023-12-08 | ||
520 | |a Embodiments of the disclosure concern methods and compositions that facilitate determination of a suitable therapy for an individual in need thereof. In specific embodiments, the individual has ER+ breast cancer of a specific subtype that renders them suitable for a particular therapy and/or renders them unsuitable for a particular therapy. In specific cases, gene expression analysis determines that an individual is of Luminal B subtype and the individual is suited for combination therapy of one or more aromatase inhibitors and one or more selective estrogen receptor degraders (SERDs) and/or is not suitable for chemotherapy. | ||
650 | 4 | |a bio | |
650 | 4 | |a tec | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a che | |
650 | 4 | |a C12Q: Measuring or testing processes involving enzymes, nucleic acids or microorganisms (immunoassay g01n0033530000); compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processes | |
650 | 4 | |a 615 | |
700 | 0 | |a ANURAG MEENAKSHI |4 aut | |
700 | 0 | |a PEROU CHARLES M |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 19. Okt. |
773 | 1 | 8 | |g year:2023 |g day:19 |g month:10 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/87935904/publication/WO2023172891A1?q=WO2023172891 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
936 | u | w | |j 2023 |b 19 |c 10 |
951 | |a AR | ||
952 | |j 2023 |b 19 |c 10 |